Novartis AG ADR
- Industria
- Pharmaceuticals
- Bolsa
- EE. UU.
- País / Región
- USA
- Fecha de salida a bolsa
- 18 de noviembre de 1991
- Empleados
- 75.267
- Sitio web
- www.novartis.com
Rango de valoración compuesto · conservador $100–$115 / razonable $125–$155 / optimista $170–$195. A $156.11, Entre el rango razonable y el optimista.
Al publicar $149.16 (8 de junio de 2026)
Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Historia
Novartis AG was formed in 1996 through the merger of the Swiss companies Ciba-Geigy and Sandoz Laboratories and is headquartered in Basel, Switzerland. The company progressively narrowed its focus, spinning off Syngenta (agrochemicals) in 2000 and Alcon (eye-care devices) in July 2018; Vas Narasimhan became CEO in February 2018. In October 2023 it completed the spinoff of its generics and biosimilars unit, Sandoz Group AG, transforming Novartis into a pure-play innovative-medicines company. It has also expanded through acquisitions including The Medicines Company (2020), MorphoSys AG (2024) and Anthos Therapeutics (2025).
Posición en el sector
Novartis is one of the world's ten largest pharmaceutical companies, focused on innovative medicines across cardiovascular, oncology, immunology, neuroscience and rare diseases, with about 75,267 employees and roughly $56.6B in 2025 revenue. Its 2024 R&D spending of $11.4B (around 20% of revenue) ranks among the global top five, supported by a deep pipeline of roughly 25 Phase III and about 70 Phase II candidates and 25 FDA approvals in 2020-2025. It is also the leader in radioligand therapy, with Pluvicto being the first FDA-approved RLT for metastatic prostate cancer.
Aún no hay análisis sobre este valor en tu idioma.